Alterations of T-cell surface markers in older women with persistent human papillomavirus infection.
We previously reported decreased lymphocyte proliferative responses among older women with persistent human papillomavirus (HPV) infection. To characterize the phenotype of peripheral lymphocytes associated with persistent HPV infection, we evaluated the expression of different cell surface markers in peripheral blood mononuclear cells (PBMCs) from a case-control study within a 10,049 woman population-based cohort study in Guanacaste, Costa Rica. Women in the cohort aged 46-74 and with HPV results at their 5th year anniversary visit were considered, and all women (n = 87) with persistent HPV infections, all women (n = 196) with transient HPV infections and a random sample of HPV DNA-negative women (n = 261) frequency-matched to cases on age were selected for this study. A median of 3 years after the case-control matching visit, cervical cells were collected for liquid-based cytology and repeat HPV DNA genotyping. Blood was obtained from which PBMCs were extracted and cryopreserved for immunological phenotyping via flow cytometry. Significant increases in risk of HPV persistence were observed for 3 marker subsets indicative of immune cell activation/differentiation. Relative risk estimates were 5.4 (95% CI = 2.2-13.3) for CD69(+)CD4(+), 2.6 (95% CI = 1.2-5.9) for HLADR(+)CD3(+)CD4(+) and 2.3 (95% CI = 1.1-4.7) for CD45RO(+)CD27(-)CD8(+). A significant decrease in HPV persistence was observed for a subset marker indicative of an immature, undifferentiated memory state CD45RO(+)CD27(+)CD4(+) (OR = 0.36; 95% CI = 0.17-0.76). Adjustment for these markers only partially explained the previously reported association between decreased lymphoproliferative responses and persistent HPV infection. Whether phenotypic alterations observed predispose to HPV persistence or result from it should be the focus of future studies.
Rodríguez
Ana Cecilia
AC
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. acrodriguez@racsa.co.cr
García-Piñeres
Alfonso J
AJ
Hildesheim
Allan
A
Herrero
Rolando
R
Trivett
Matthew
M
Williams
Marcus
M
Atmella
Ivannia
I
Ramírez
Margarita
M
Villegas
Maricela
M
Schiffman
Mark
M
Burk
Robert
R
Freer
Enrique
E
Bonilla
José
J
Bratti
Concepción
C
Pinto
Ligia A
LA
D000328:Adult; D000368:Aged; D052685:Alphapapillomavirus / Q000235:genetics / Q000302:isolation & purification; D015703:Antigens, CD / Q000032:analysis / Q000276:immunology; D002908:Chronic Disease; D015331:Cohort Studies; D003127:Colposcopy; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000276:immunology*; D016133:Polymerase Chain Reaction / Q000379:methods; D013601:T-Lymphocytes / Q000276:immunology*; D014412:Tumor Virus Infections / Q000235:genetics; D002578:Uterine Cervical Dysplasia / Q000150:complications / Q000235:genetics
D015703:Antigens, CD; D004279:DNA, Viral
Eur J Cancer. 1999 Mar;35(3):490-7
10448305
Int J Cancer. 2002 Feb 10;97(5):654-9
11807793
J Clin Pathol. 2005 Oct;58(10):1096-100
16189158
BJOG. 2002 Jan;109(1):96-8
11845815
Cancer Res. 2004 Aug 1;64(15):5449-55
15289354
J Infect Dis. 2005 Jun 1;191(11):1808-16
15871112
Sex Transm Dis. 2007 Jul;34(7):494-502
17237737
Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):807-13
9332763
J Infect Dis. 1999 Nov;180(5):1429-35
10515800
J Gen Virol. 1999 Feb;80 ( Pt 2):399-408
10073700
J Natl Cancer Inst. 1997 Feb 5;89(3):245-50
9017005
J Natl Cancer Inst. 2005 Apr 20;97(8):577-86
15840880
J Virol. 2007 Jun;81(11):5766-76
17376923
J Infect Dis. 2005 Jun 1;191(11):1796-807
15871111
J Immunol. 2004 Jul 1;173(1):673-81
15210831
J Clin Pathol. 2002 Apr;55(4):244-65
11919208
Lancet Infect Dis. 2007 Jul;7(7):453-9
17597569
Int J Cancer. 2006 Dec 1;119(11):2677-84
16991121
Arthritis Rheum. 2006 Jul;54(7):2184-97
16802356
Rev Panam Salud Publica. 1997 May;1(5):362-75
9180057
J Infect Dis. 2007 Jun 1;195(11):1582-9
17471427
J Med Virol. 2002 Nov;68(3):417-23
12226831
N Engl J Med. 1998 Feb 12;338(7):423-8
9459645
J Infect Dis. 2005 Mar 1;191(5):731-8
15688287
Immunology. 2006 Feb;117(2):220-8
16423058
J Immunol. 2005 Dec 15;175(12):8218-25
16339561
Cancer Res. 1996 Sep 1;56(17):3967-74
8752165
Cancer Res. 2006 Nov 15;66(22):11070-6
17108147
J Virol. 2007 Jul;81(14):7759-65
17409149
Mech Ageing Dev. 2004 Sep;125(9):615-8
15491679
N Engl J Med. 2003 Feb 6;348(6):489-90
12571255
J Pathol. 1998 Mar;184(3):283-90
9614381
J Immunol Methods. 2006 Jun 30;313(1-2):209-13
16737707
Cancer Res. 1998 Apr 15;58(8):1700-6
9563486
Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):101-6
11219765
J Autoimmun. 1996 Dec;9(6):731-7
9115575
Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):483-8
12010863
Rev Panam Salud Publica. 2004 Feb;15(2):75-89
15030652
Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):485-90
12814991
Nat Med. 2002 Apr;8(4):379-85
11927944
Clin Exp Immunol. 2007 Nov;150(2):199-209
17937675
Virus Res. 2002 Nov;89(2):229-40
12445662